EFG Asset Management North America Corp. Takes $1.98 Million Position in Icon Plc $ICLR

EFG Asset Management North America Corp. bought a new position in shares of Icon Plc (NASDAQ:ICLR) during the third quarter, HoldingsChannel reports. The fund bought 11,336 shares of the medical research company’s stock, valued at approximately $1,984,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Geneos Wealth Management Inc. grew its position in Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the last quarter. Spire Wealth Management boosted its stake in shares of Icon by 10.1% during the third quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock worth $119,000 after buying an additional 62 shares during the period. Mutual Advisors LLC grew its holdings in shares of Icon by 3.6% during the second quarter. Mutual Advisors LLC now owns 2,698 shares of the medical research company’s stock worth $392,000 after buying an additional 93 shares during the last quarter. Private Trust Co. NA increased its position in Icon by 200.0% in the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 94 shares during the period. Finally, Hunter Perkins Capital Management LLC raised its stake in Icon by 0.4% during the 2nd quarter. Hunter Perkins Capital Management LLC now owns 22,399 shares of the medical research company’s stock valued at $3,258,000 after acquiring an additional 97 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Bank of America downgraded Icon from a “buy” rating to a “neutral” rating and set a $195.00 target price on the stock. in a research note on Monday, December 15th. Leerink Partners reiterated an “outperform” rating on shares of Icon in a research report on Monday, January 5th. Barclays upped their price objective on shares of Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Mizuho set a $216.00 target price on shares of Icon in a report on Friday, January 9th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Icon in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $200.60.

Icon Stock Performance

Shares of ICLR opened at $187.97 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 52-week low of $125.10 and a 52-week high of $211.00. The company has a 50-day simple moving average of $182.54 and a 200-day simple moving average of $176.05. The company has a market capitalization of $15.18 billion, a PE ratio of 25.44, a P/E/G ratio of 3.96 and a beta of 1.26.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.